Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during the specified Class Period from June 22, 2023, to June 24, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false and misleading statements about ELEVIDYS, which is intended for patients with Duchenne muscular dystrophy, including significant safety risks and failure to detect severe side effects [5]. - It is alleged that the adverse events from ELEVIDYS treatment would lead to a halt in recruitment and dosing in trials, attract regulatory scrutiny, and increase risks around the therapy's approvals [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record, including recovering hundreds of millions for investors [4]. - Investors are advised to select qualified legal counsel with a proven history in similar cases, as not all firms have comparable experience or resources [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Red Cat Holdings, Inc. (NASDAQ: RCAT) between March 18, 2022 and January 15, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Red Cat securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF) securities between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants made false a ...

ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Petco’s business, operations, and prospects, including allegations that: (i) Petco’s pandemic-related tailwinds were unsustainable, as was its business model of selling primarily p ...

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. FTRE investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Fortrea overestimated the amount of revenue the long-term projects in its portfolio, the Pre-Spin Projects, ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Hims & Hers Health, Inc. common stock during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and partnerships [1][5]. Group 1: Class Action Details - The class action lawsuit is filed for purchasers of Hims common stock between April 29, 2025, and June 23, 2025, inclusive [1]. - Investors who purchased Hims stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. Group 2: Allegations Against Hims - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for Hims subscribers [5]. - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo, which was supposed to ensure continued access to Wegovy, and that positive statements were made about the partnership that misled investors [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Organon & Co. ("Organon" or the "Company") (NYSE: OGN) investors of a class action representing investors that bought securities between October 31, 2024 to April 30, 2025, inclusive (the "Class Period"). Organon investors have until July 22, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, b ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 30, 2025 (GLOBE NEWSWIRE) --  The Portnoy Law Firm advises DoubleVerify Holdings, Inc. ("DoubleVerify" or the "Company") (NYSE: DV) investors of a class action representing investors that bought securities between November 10, 2023 and February 27, 2025, inclusive (the "Class Period"). DoubleVerify investors have until July 21, 2025 to file a lead plaintiff motion. Investors are encouraged to contact ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Red Cat Holdings, Inc. ("Red Cat" or the "Company") (NASDAQ: RCAT) investors of a class action representing investors that bought securities between March 18, 2022 and January 15, 2025, inclusive (the "Class Period"). Red Cat investors have until July 22, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley ...

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged violations of securities laws, specifically related to misleading statements made by the company during a defined class period [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Hims & Hers securities between April 29, 2025, and June 23, 2025 [2]. - Investors are encouraged to contact the Schall Law Firm before August 25, 2025, to discuss their rights and potential participation in the lawsuit [2][3]. Group 2: Allegations Against the Company - The complaint alleges that Hims & Hers made false and misleading statements regarding its marketing practices, particularly in relation to the promotion of products that could jeopardize patient safety [4]. - The company faced the risk of having its partnership with Novo Nordisk terminated due to these deceptive marketing activities [4]. - The misleading public statements resulted in financial damages to investors once the truth about the company's practices was revealed [4].